Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health (GH) received CE-marking in Europe for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced ER-positive breast cancer. This approval follows prior U.S. and Japan approvals and marks the 31st CDx approval for Guardant Health. The test identifies ESR1 mutations via blood draw, aiding treatment decisions.
How this was made
The 30-second read
Why it matters
The CE-marking under the EU in Vitro Diagnostic Regulation enables use of Guardant360 CDx in Europe to identify ER-positive, HER2-negative locally advanced or metastatic breast cancer patients who may benefit from camizestrant.
Market read
This is a company-specific regulatory milestone that can expand EU companion-diagnostic utilization for camizestrant, reinforcing Guardant’s CDx platform growth.
What to watch
Adoption depends on payer coverage, lab network readiness, and clinician uptake of ESR1 mutation testing via blood draw; the article provides no sales or reimbursement details.
Background
Guardant360 CDx is a liquid biopsy genomic profiling test used as a companion diagnostic for therapies including camizestrant (ETCAMAH).
Ticker impact
Guardant Health says Guardant360 CDx received CE-marking as a companion diagnostic for AstraZeneca’s camizestrant in ER-positive, HER2-negative advanced breast cancer.
Likely modest positive bias as the market prices incremental EU uptake and reinforces the CDx franchise tied to camizestrant.
The article is a direct regulatory approval for Guardant’s own product (CE-marking) and cites prior US and Japan approvals, implying a broader rollout rather than a one-off event.
Market effects
Supports the broader CDx-liquid biopsy adoption narrative in breast cancer and may strengthen competitive positioning for oncology diagnostics in Europe.
Improves Guardant’s EU commercialization pathway for companion diagnostic use, potentially increasing near-term testing demand in European clinics.
Adds to the global expansion sequence (US, Japan, now Europe) for Guardant360 CDx tied to camizestrant.
Counterpoint
CE-marking does not guarantee immediate reimbursement or rapid clinical uptake across all EU markets, so near-term revenue impact may be slower than bulls expect.
Key entities
- companyGuardant Health, Inc.
Receives CE-marking for Guardant360 CDx as a companion diagnostic for camizestrant in advanced ER-positive breast cancer.
- companyAstraZeneca
Its camizestrant (ETCAMAH) is the therapy for which Guardant360 CDx is approved as a companion diagnostic in Europe.
- productGuardant360 CDx
Liquid biopsy CDx that detects genomic alterations and supports ESR1 mutation testing via blood draw.
- drugETCAMAH (camizestrant)
AstraZeneca’s oral SERD and complete ER antagonist referenced as the therapy companioned with Guardant360 CDx.
